Astel­las, Seagen pave the way for Pad­cev's glob­al roll­out with full con­fir­ma­to­ry da­ta for urothe­lial can­cer in hand

Astel­las and Seagen made a big splash with their Nectin-4 tar­get­ing ther­a­py Pad­cev in late 2019, scor­ing a con­di­tion­al FDA ap­proval to tar­get urothe­lial can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER